NASDAQ, ALNY - Alnylam Pharmaceuticals
We are a biopharmaceutical company developing novel therapeutics based on RNA
interference, or RNAi. RNAi is a naturally occurring biological pathway within
cells for selectively silencing and regulating the expression of specific genes.
Since many diseases are caused by the inappropriate activity of specific genes,
the ability to silence genes selectively through RNAi could provide a new way to
treat a wide range of human diseases. We believe that drugs that work through
RNAi have the potential to become a broad new class of drugs, like small
molecule, protein and antibody drugs. Using our intellectual property and the
expertise we have built in RNAi, we are developing a set of biological and
chemical methods and know-how that we apply in a systematic way to develop RNAi
therapeutics for a variety of diseases. ...
Read SEC Filing on NASDAQ.com »